pharmaceutical investing Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
pharmaceutical investing Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA Robotic Surgical System
pharmaceutical investing Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
pharmaceutical investing Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
pharmaceutical investing Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
pharmaceutical investing Johnson & Johnson presents new IMAAVY® data at European Academy of Neurology 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
pharmaceutical investing Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
New TALVEY® plus DARZALEX FASPRO® data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
IMAAVY® demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia , an autoantibody-driven disease with no FDA-approved therapies
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
Bahia Metals Advances Initial Mineral Resource Estimate for Sulphide Nickel Copper Cobalt PGM Project
Ni-Co Énergie Nomme Robert Wares, Géo., à Titre de Conseiller Technique et Annonce l'Octroi d'Options d'Achat d'Actions
